TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00460811

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Linaclotide Acetate
Description: Oral, once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Linaclotide Acetate
Description: Oral, once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Linaclotide Acetate
Description: Oral, once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Linaclotide Acetate
Description: Oral, once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo
Description: Oral, once daily
Study: NCT01100086

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reformulated OXY (oxycodone HCl)
Description: Reformulated OXY 10-mg tablet x 1 dose taken without food

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Original OxyContin® (OXY) (oxycodone HCl)
Description: Original OxyContin® (OXY) 10-mg tablet x 1 dose taken without food
Study: NCT00529503

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGN-40
Description: 2-8 mg/kg IV. Cycle 1: Days -1, 3, 8, 15; Cycles 2, 3: Days 1, 8, 15.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Volume as equivalent to corresponding SGN 40 dose IV. Cycle 1: Days -1, 3, 8, 15. Cycles 2, 3: Days 1, 8, 15.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab
Description: 375 mg/m2 IV. Cycle 1: Day -2; Cycles 2, 3: Day 1

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: rituximab
Description: 375 mg/m2 IV. Cycle 1: Day -2; Cycles 2, 3: Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: 100 mg/m2 IV. Cycles 1-3: Days 1, 2 and 3.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: etoposide
Description: 100 mg/m2 IV. Cycles 1-3: Days 1, 2 and 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: AUC=5 mg/mL min IV. Cycles 1-3: Day 2.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: carboplatin
Description: AUC=5 mg/mL min IV. Cycles 1-3: Day 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ifosfamide
Description: 5 g/m2 24 hr. IV infusion. Cycles 1-3: Day2.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ifosfamide
Description: 5 g/m2 24 hr. IV infusion. Cycles 1-3: Day2.
Study: NCT00404391

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocodone/Acetaminophen Extended Release
Description: 1 tablet every 12 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocodone/Acetaminophen Extended Release
Description: 2 tablets every 12 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 tablets every 12 hours
Study: NCT01051791

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus 10mg daily
Description: RAD001 is a pill that will be taken orally (by mouth), at a dose of 10 mg, once a day for 28 days.
Study: NCT04295083

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: clay based group study
Description: Clay based group work sessions were applied to the experimental group for 60-90 minutes once a week for 6 weeks. The sessions are composed of structured or semi-structured activities prepared for the purpose of the literature by the researcher for the purposes such as acquiring new solutions and life skills to reduce loneliness and hopelessness of individuals aged 65 and over, and sharing their feelings, thoughts, and memories with other individuals. Clay Study Activity Booklet . Four expert opinions were obtained for the booklet created. Methods such as narration, sharing experiences, group practice, question-answer, learning by doing, imagining were used in the activity program. The physical, psychological, social and mental characteristics of the elderly were taken into consideration in the selection of these methods.
Study: NCT02166931

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Chicken Essence
Description: BRAND'S® Chicken Essence of 70cc daily for 2 weeks Placebo 70 cc daily for 2 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Chicken Essence
Description: BRAND'S® Chicken Essence of 70cc daily for 2 weeks Placebo 70 cc daily for 2 weeks
Study: NCT03640533

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nanit-Insights
Description: Nanit-Insights is an app-based intervention that provides personalized sleep tips to parents.
Study: NCT04747119

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: muscle energy technique
Description: the patient was supine and the therapist fix the lower limb of the affected side then ask the patient to perform isometric contraction for abductors maintained for 3-5 seconds, then the patient was instructed to stop, exhale and relax then the therapist perform further adducted the patient's knee of the affected side as a stretching exercise for Three to five repetitions of these directions were performed.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional selected physical therapy
Description: 1. life style modification~2. Transcutaneous electrical nerve stimulation (TENS)~3. Flexibility stretching exercises to the hip flexors

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional selected physical therapy
Description: 1. life style modification~2. Transcutaneous electrical nerve stimulation (TENS)~3. Flexibility stretching exercises to the hip flexors
Study: NCT03391219

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: injection bevacizumab
Description: 1.25 mg/0.05 cc bevacizumab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: injection Combined Bevacizumab and Fasudil
Description: 1.25 mg/0.05 cc bevacizumab and 0.15mg/0.05 cc fasudil
Study: NCT02000960

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triheptanoin
Description: Triheptanoin (C7 oil) is a triglyceride of the anaplerotic odd-chain fatty acid heptonate.
Study: NCT02367118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01997476

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Combined EUS, e-PFT and sEUS Testing
Description: advantage of combined EUS, ePFT \& sEUS testing to provide a more definitive diagnostic assessment, rather than each test alone.~Establish the advantage of reduced time and cost of combining EUS and ePFT, rather than when done separately.
Study: NCT04287257

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fracture Healing Patch (FHP)
Description: The Fracture Healing Patch (FHP) is an external silicone patch that contains inside micro-electronic modulus, which generates a pulsed electromagnetic field (PEMF) to enhance and improve fracture healing. The FHP is placed under the cast at the fracture site. Throughout the treatment period the FHP produces a pulsed electromagnetic field. The FHP houses a battery, a microelectronic module and a coil that produce the PEMF.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Fracture Healing Patch (FHP)
Description: The Fracture Healing Patch (FHP) is an external silicone patch that contains inside micro-electronic modulus, which generates a pulsed electromagnetic field (PEMF) to enhance and improve fracture healing. The FHP is placed under the cast at the fracture site. Throughout the treatment period the FHP produces a pulsed electromagnetic field. The FHP houses a battery, a microelectronic module and a coil that produce the PEMF.
Study: NCT00840957

Intervention type: BIOLOGICAL
Intervention: infliximab
Description: chimeric monoclonal antibody to Tumor Necrosis Factor-alpha
Study: NCT03866512

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Forearm immobilization
Description: Two days of forearm immobilization

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Forearm immobilization
Description: Two days of forearm immobilization

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Forearm immobilization
Description: Two days of forearm immobilization
Study: NCT04477148

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: endotracheal intubation
Description: patients were intubated with 3 different blades

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: endotracheal intubation
Description: patients were intubated with 3 different blades

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: endotracheal intubation
Description: patients were intubated with 3 different blades
Study: NCT01757002

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Teens randomized to the experimental arm will receive 4 sessions plus a booster of web-based, tailored asthma management.
Description: Web-based, computer-tailored asthma management intervention delivered in 4 sessions, plus a 6 month booster.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Teens in the control group will receive generic, web-based asthma education.
Description: Web-based, generic asthma management intervention delivered in 4 sessions.
Study: NCT02512302

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SUN-101 via eFlow nebulizer
Description: 50 mcg glycopyrrolate via Electronic Nebulizer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SUN-101 via eFlow nebulizer with activated charcoal
Description: 50 mcg glycopyrrolate via Electronic Nebulizer with activated charcoal

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Seebri® Breezhaler®
Description: 63 mcg glycopyrronium bromide (50 mcg glycopyrronium) via DPI

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Seebri® Breezhaler® with activated charcoal
Description: 63 mcg glycopyrronium bromide (50 mcg glycopyrronium) via DPI with activated charcoal

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glycopyrrolate Injection
Description: 50 mcg glycopyrrolate via IV
Study: NCT00504712

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone
Description: Sustanon- 200mg- Intramuscular testosterone every 2 weeks
Study: NCT04363801

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab 400mg
Description: Administered by IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tislelizumab 400mg
Description: Administered by IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab 400mg
Description: Administered by IV infusion
Study: NCT00504712

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: Saline injection every two weeks
Study: NCT03418688

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: COR388
Description: COR388 administered for 10 or 28 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered for 10 or 28 days.
Study: NCT03194971

Intervention type: OTHER
Intervention: Tumor samples from patients treated with TTFields at initial diagnosis.
Description: Pathological assessment of tumor cellularity, apoptosis, and quantitative histo-morphometry of residual tumor cells will be performed. Each metric will be statistically compared between groups.

Intervention type: DEVICE
Intervention: Tumor samples from patients treated with TTFields at tumor recurrence.
Description: Pathological assessment of tumor cellularity, apoptosis, and quantitative histo-morphometry of residual tumor cells will be performed. Each metric will be statistically compared between groups.
Study: NCT01478776

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: omega-3
Description: 4 cap 1 gr omega-3 per day for 10 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: patient with type 2 diabetes who receive 4 cap placebo/day for 10 weeks
Study: NCT01035294

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mindfulness based intervention (MBI)
Description: Eight, phone delivered, individual mindfulness sessions. Each training session will last 30 minutes (20 minutes for intervention + an additional 10 minutes for questions, answers, and for scheduling the next intervention. Patients will also receive instructions to practice at home every day, at least once a day, for at least 15 minutes. An audio CD containing guided mindfulness exercises will be given to the patient at the beginning of the study, to guide them during their home practice. The CD consists of sequences of different mindfulness techniques, consistent with the techniques learned during each session with the instructor. Each patient will record the minutes of mindfulness practice in a diary to be kept daily.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: usual care
Description: The UC group will be offered the standard care planned by the hospital, which includes the routine care provided by the electrophysiology team and other health care professionals that the patient may see over the course of the ICD experience. All patients receive a number of printed education materials and participate to support meetings for ICD patients four times a year. Being part of the standard care offered at UMass Memorial Medical Center, these meetings are offered to all patients regardless of their assignment (thus including patients assigned to the MBI arm).
Study: NCT02927951

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: 150mg bid

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 150mg bid
Study: NCT01749826

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine Sulfate
Description: 15mg sustained release morphine sulfate, with a maximum dose of 120mg. Patients will be titrated up to a maximum dose of 8 pills a day for one month.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine Sulfate
Description: 15mg sustained release morphine sulfate, with a maximum dose of 120mg. Patients will be titrated up to a maximum dose of 8 pills a day for one month.
Study: NCT02301013

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Urinary incontience surgery
Description: Surgery for stress or mixed urinary incontience

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 300 cc saline
Study: NCT02848144

Intervention type: OTHER
Group type: OTHER
Intervention: blood samples

Intervention type: OTHER
Group type: OTHER
Intervention: blood samples

Intervention type: OTHER
Group type: OTHER
Intervention: Collection of nosocomial infections

Intervention type: OTHER
Group type: OTHER
Intervention: Collection of nosocomial infections
Study: NCT04651855

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesenchymal stem cells isolated from Wharton's jelly
Description: Intrathecal administration of mesenchymal stem cells
Study: NCT00778869

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Remicade
Description: Remicade will be given at Weeks 0, 2, and 6 and then every 8 weeks up to Week 54.
Study: NCT04251481

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PET/MRI with FDG
Description: For the PET/MRI scans, an intravenous (IV) catheter (thin tube) will be used to administer dyes (contrast) for both the MRI and PET portions of the examination. The dye for the PET portion will be 18F-fluorodeoxyglucose (FDG). FDG is an FDA-approved radioactive substance (isotope) that contains chemicals that can be traced by PET/MRI. The dye for the MRI portion will be a gadolinium based contrast medium which is also an FDA-approved substance that makes certain tissues, abnormalities or disease processes more clearly visible on MRI scans. MRI uses a strong magnetic field to create images of the body. Subjects will be asked to lie on a table that will slide into the scanner; Wear earplugs to reduce the noise made by the MRI scanner and lie still throughout the time in the scanner.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: MRI scan without contrast
Description: MRI uses a strong magnetic field to create images of the body. Subjects will be asked to lie on a table that will slide into the scanner to scan the neck ; Wear earplugs to reduce the noise made by the MRI scanner and lie still throughout the time in the scanner.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: MRI scan without contrast
Description: MRI uses a strong magnetic field to create images of the body. Subjects will be asked to lie on a table that will slide into the scanner to scan the neck ; Wear earplugs to reduce the noise made by the MRI scanner and lie still throughout the time in the scanner.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: MRI with gadolinium
Description: For the MRI scans, an intravenous (IV) catheter (thin tube) will be used to administer dyes (contrast) for MR scans. The dye for the MRI will be a gadolinium based contrast medium which is also an FDA-approved substance that makes certain tissues, abnormalities or disease processes more clearly visible on MRI scans. MRI uses a strong magnetic field to create images of the body. Subjects will be asked to lie on a table that will slide into the scanner; Wear earplugs to reduce the noise made by the MRI scanner and lie still throughout the time in the scanner.
Study: NCT00116818

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW685698X aqueous nasal spray
Study: NCT04363801

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: Administered by IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Administered by IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine 1000mg/ m2 BID
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine 1000mg/ m2 BID
Description: Administered orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin Calcium
Description: Administered by IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin Calcium
Description: Administered by IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluorouracil
Description: Administered by IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Administered by IV infusion
Study: NCT04034641

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bifidobacterium tetrad live bacteria tablet plus Helicobacter pylori quadruple eradication therapy
Description: On day 1-14: Standard therapy: esomeprazole magnesium enteric-coated tablets, amoxicillin granules (A Mo Xian), furazolidone tablets, bismuth potassium citrate granules (Li Zhu De Le) are taken twice a day, once in the morning and once in the evening. Esomeprazole magnesium enteric-coated tablets and bismuth potassium citrate granules (Li Zhu De Le) should be taken 30min before meal; amoxicillin granules (A Mo Xian) and furazolidone tablets should be taken 30min after meal. Probiotic: Bifidobacterium tetrad live bacteria tablets should be taken at noon once a day (30 min after meal ), 9 tablets per time. On day 15-28: Probiotic: Bifidobacterium tetrad live bacteria tablets, taken at noon once a day (30min after meal), 9 tablets per time.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bifidobacterium tetrad live bacteria tablet placebo plus Helicobacter pylori quadruple eradication therapy
Description: On day 1-14: Standard therapy: esomeprazole magnesium enteric-coated tablets, amoxicillin granules (A Mo Xian), furazolidone tablets, bismuth potassium citrate granules (Li Zhu De Le) are taken twice a day, once in the morning and once in the evening. Esomeprazole magnesium enteric-coated tablets and bismuth potassium citrate granules (Li Zhu De Le) should be taken 30min before meal; amoxicillin granules (A Mo Xian) and furazolidone tablets should be taken 30min after meal. Placebo: Bifidobacterium tetrad live bacteria tablet placebos should be taken at noon once a day ( 30 min after meal ), 9 tablets per time. On day 15-28: Placebo: Bifidobacterium tetrad live bacteria tablet placebos, taken at noon once a day (30min after meal), 9 tablets per time.
Study: NCT00907673

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Automatic Fluid Shunt System
Description: Fully implantable peritoneal catheter, bladder catheter, and pump
Study: NCT01138904

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: irinotecan, oxaliplatin
Description: OXIR: FOLFOX -\> FOLFIRI~IROX: FOLFIRI -\> FOLFOX~FOLFOX REGIMEN~D1 Oxaliplatin 85mg/m2 + 5DW 500ml MIV over 120min D1,D2 Leucovorin 50mg IV Push D1,D2 5-Fluorouracil 400mg/m2 IV Push D1,D2 5-Fluorouracil 600mg/m2 + 5DW 1000ml MIV over 22hr~Every 2 weeks~FOLFILI REGIMEN~D1 Irinotecan 150mg/m2 + 5DW 500ml MIV over 120min D1,D2 Leucovorin 50mg IV Push D1,D2 5-Fluorouracil 400mg/m2 IV Push D1,D2 5-Fluorouracil 600mg/m2 + 5DW 1000ml MIV over 22hr~Every 2 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxaliplatin, irinotecan
Description: FOLFOX REGIMEN~D1 Oxaliplatin 85mg/m2 + 5DW 500ml MIV over 120min D1,D2 Leucovorin 50mg IV Push D1,D2 5-Fluorouracil 400mg/m2 IV Push D1,D2 5-Fluorouracil 600mg/m2 + 5DW 1000ml MIV over 22hr~Every 2 weeks~FOLFILI REGIMEN~D1 Irinotecan 150mg/m2 + 5DW 500ml MIV over 120min D1,D2 Leucovorin 50mg IV Push D1,D2 5-Fluorouracil 400mg/m2 IV Push D1,D2 5-Fluorouracil 600mg/m2 + 5DW 1000ml MIV over 22hr~Every 2 weeks
Study: NCT03238937

Intervention type: DEVICE
Group type: OTHER
Intervention: Phrenic nerve stimulator
Description: Implantation of phrenic nerve stimulator
Study: NCT03591341

Intervention type: DIAGNOSTIC_TEST
Intervention: melatonin level in pumped breast milk
Description: diagnostic test of melatonin level in pumped breast milk
Study: NCT03135951

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPI-2012
Description: Supplied in prefilled, single-use syringes for subcutaneous injection and administered on Day 2 of each cycle.
Study: NCT03898206

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breaking up sitting with walking breaks
Description: See Breaking up sitting with walking breaks arm description
Study: NCT00755599

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: no-stirrup vaginal examination
Description: Vaginal speculum examination done with feet on table extender.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vaginal speculum examination done with stirrups.
Description: Speculum examination done with feet in stirrups.
Study: NCT03910036

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: platelet rich plasma
Description: Thirty ml of venous blood was taken from every patient and collected in sodium citrated sterile tubes. Platelet concentrates obtained by adjusting centrifuge at 1800 rpm for 15 min to separate erythrocytes, then at 3500 rpm for 10 min to concentrate the platelets. The preparation was done by a single laboratory technician. Thus 5 ml of PRP were obtained, 0.2 mL of 10% calcium chloride was added to the final product to activate the platelets and injected immediately without storage.
Study: NCT03019237

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti-IgE
Description: intranasal anti-IgE
Study: NCT03898206

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prolonged sitting
Description: See Prolonged sitting arm description